# Vivatides Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivatides-therapeutics

- Industry: Healthcare
- Headquarters: Hong Kong, Hong Kong SAR - China
- Total disclosed funding: $64M
- Latest round: Series A (Apr 10, 2026)
- Investors on record: 4

## About

Founded in 2025 and based in Hongkong, Vivatides Therapeutics Limited, dba Vivatides Therapeutics, is a biotechnology company developing extra-hepatic targeted small-nucleic-acid therapeutics. In April 2026, Vivatides Therapeutics raised USD 54 million in Series A funding led by Qiming Venture Partners, with participation from HighLight Capital, TF Capital, Apricot Capital.
Vivatides Therapeutics is developing a preclinical extra-hepatic targeted oligonucleotide delivery platform and associated therapeutic pipelines (including both ASO and siRNA approaches) aimed at enabling targeted delivery beyond the liver. Public descriptions emphasize platform differentiation at the design level to overcome extra-hepatic delivery challenges.
Vivatides Therapeutics generates revenue through partnering/licensing deals with larger biopharma companies (upfront payments, milestones, royalties), sponsored R&D or co-development agreements, and non-dilutive funding such as government grants or research contracts.

## Funding rounds

- Series A, Apr 10, 2026, $54M — Qiming Venture Partners, HighLight Capital, TF Capital, Apricot Capital
- Seed, Aug 20, 2025, $10M — Qiming Venture Partners, Apricot Capital

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Seed, Series A
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Seed, Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series A
- TF Capital — Series A